Recent News

• 05.23.2025 - AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
• 05.19.2025 - AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
• 05.14.2025 - AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 04.25.2025 - AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
• 04.21.2025 - AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
• 04.21.2025 - AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
• 03.27.2025 - AEON Biopharma Announces CEO Transition
• 03.24.2025 - AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.04.2025 - AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
• 02.24.2025 - AEON Biopharma, Inc. Announces Reverse Stock Split

Recent Filings

• 08.11.2022 - D Notice of Exempt Offering of Securities
• 08.11.2022 - D Notice of Exempt Offering of Securities
• 12.29.2021 - RW Registration Withdrawal Request
• 10.07.2021 - S-1/A General form for registration of securities under the Securities Act of 1933
• 10.06.2021 - S-1/A General form for registration of securities under the Securities Act of 1933
• 10.04.2021 - S-1/A General form for registration of securities under the Securities Act of 1933
• 09.17.2021 - S-1 General form for registration of securities under the Securities Act of 1933
• 09.14.2021 - DRS/A Draft Registration Statement
• 07.21.2021 - DRS/A Draft Registration Statement